This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
===== Electrode ===== In 2010, researchers first reported creating a graphene-silicon heterojunction solar cell, where graphene served as a transparent electrode and introduced a built-in electric field near the interface between the graphene and n-type silicon to help collect charge carriers. In 2012 researchers reported efficiency of 8.6% for a prototype consisting of a silicon wafer coated with trifluoromethanesulfonyl-amide (TFSA) doped graphene. Doping increased efficiency to 9.6% in 2013. In 2015 researchers reported efficiency of 15.6% by choosing the optimal oxide thickness on the silicon. This combination of carbon materials with traditional silicon semiconductors to fabricate solar cells has been a promising field of carbon science. In 2013, another team reported 15.6% percent by combining titanium oxide and graphene as a charge collector and perovskite as a sunlight absorber. The device is manufacturable at temperatures under 150 °C (302 °F) using solution-based deposition. This lowers production costs and offers the potential using flexible plastics. In 2015, researchers developed a prototype cell that used semitransparent perovskite with graphene electrodes. The design allowed light to be absorbed from both sides. It offered efficiency of around 12 percent with estimated production costs of less than $0.06/watt. The graphene was coated with PEDOT:PSS conductive polymer (polythiophene) polystyrene sulfonate). Multilayering graphene via CVD created transparent electrodes reducing sheet resistance.
==== NF-κB ==== NF-κB activation is initiated by DAG, the second, membrane bound product of PLCγ hydrolyzation of PIP2. DAG binds and recruits protein kinase C θ (PKCθ) to the membrane where it can activate the membrane bound scaffold protein CARMA1. CARMA1 then undergoes a conformational change which allows it to oligomerize and bind the adapter proteins BCL10, CARD domain and MALT1. This multi-subunit complex binds the ubiquitin ligase TRAF6. Ubiquitination of TRAF6 serves as scaffold to recruit NEMO, IκB kinase (IKK) and TAK1. TAK 1 phosphorylates IKK, which in turn phosphorylates the NF-κB inhibitor I-κB, leading to the ubiquitination and subsequent degradation of I-κB. I-κB blocks the NLS of NF-κB therefore preventing its translocation to the nucleus. Once I-κB is degraded, it cannot bind to NF-κB and the NLS of NF-κB becomes accessible for nuclear translocation.
The International Union of Pure and Applied Chemistry (IUPAC ) is an international federation of National Adhering Organizations working for the advancement of the chemical sciences, especially by developing nomenclature and terminology. It is a member of the International Science Council (ISC). IUPAC is registered in Zürich, Switzerland, and its administrative office, known as the "IUPAC Secretariat", is in Research Triangle Park, North Carolina, United States. IUPAC was established in 1919 as the successor of the International Congress of Applied Chemistry for the advancement of chemistry. Its members, the National Adhering Organizations, can be national chemistry societies, national academies of sciences, or just other bodies representing chemists. There are a total of fifty-four National Adhering Organizations and three Associate National Adhering Organizations. IUPAC's Inter-divisional Committee on Nomenclature and Symbols (IUPAC nomenclature) is the recognized world authority in developing standards for naming chemical elements and compounds. Since its creation, IUPAC has been run by many different committees with different responsibilities. These committees run different projects; of those which include standardizing nomenclature, finding ways to bring chemistry to the world, and publishing works. IUPAC is best known for its works standardizing nomenclature in chemistry, but they have publications in many science fields including chemistry, biology, and physics.
== External links == New Scientist, 23 November 2005, "Why we cannot rely on firearm forensics" (subscription required) (Archived copy) Scientific Working Group for Gunshot Residue (SWGGSR) http://www.swggsr.org/ ENFSI EWG Firearms/GSR Working Group http://www.enfsi.eu/about-enfsi/structure/working-groups/firearms-and-gsr Gunshot Powder Residue Test http://www.meditests.com/gun-powder-test.html
Sources: en.wikipedia.org
==== Detection in body fluids ==== Morphine and its major metabolites, morphine-3-glucuronide, and morphine-6-glucuronide, can be detected in blood, plasma, hair, and urine using an immunoassay. Chromatography can be used to test for each of these substances individually. Some testing procedures hydrolyze metabolic products into morphine before the immunoassay, which must be considered when comparing morphine levels in separately published results. Morphine can also be isolated from whole blood samples by solid phase extraction (SPE) and detected using liquid chromatography-mass spectrometry (LC-MS). Ingestion of codeine or food containing poppy seeds can cause false positives. A 1999 review estimated that relatively low doses of heroin (which metabolizes immediately into morphine) are detectable by standard urine tests for 1–1.5 days after use. A 2009 review determined that, when the analyte is morphine and the limit of detection is 1 ng/ml, a 20 mg intravenous (IV) dose of morphine is detectable for 12–24 hours. A limit of detection of 0.6 ng/ml had similar results.
== History == Clinical and Vaccine Immunology (CVI) was originally launched in 1994 as Clinical and Diagnostic Laboratory Immunology. Dr. Steven D. Douglas was the Founding Editor and served as Editor in Chief until 2004. The focus and intent of the journal was to serve the new ASM Division V, Clinical and Diagnostic Immunology. Douglas was succeeded by Dr. Susan F. Plaeger, CVI's Editor in Chief until 2013. Under Plaeger's leadership, and in response to ASM members' feedback, the journal expanded its scope to include the growing field of veterinary and human vaccines. In 2006, the ASM Publications Board approved the new name Clinical and Vaccine Immunology, to reflect the inclusion of vaccine research as well as clinical immunology. The reorganization allowed CVI to attract high-quality research papers in the areas of clinical immunology and vaccinology while maintaining its interest in laboratory immunology and diagnostics. Since then, the journal has enjoyed a sustained increase in citations and impact factor. Areas of interest for CVI include microbial immunology, clinical immunology and immune mechanisms (in health and disease), veterinary immunology, and all aspects of vaccine research: development and evaluation, adjuvants, immune modulators and antigen-delivery systems, vaccine implementation, and clinical trials. The journal serves ASM members and the broad research community with the high scientific and editorial standards of the ASM Journals and the society itself.
=== Other pharmaceutical action === Salvinorin A is capable of inhibiting excess intestinal motility (e.g. diarrhea), through a combination of κ-opioid and cannabinoid (mainly CB1 receptor) receptors in inflamed but not normal gut in vivo. The mechanism of action for Salvinorin A on ileal tissue has been described as 'prejunctional', as it was able to modify electrically induced contractions, but not those of exogenous acetylcholine. Results from a study at the University of Iowa indicate that it may have potential as an analgesic and as a therapeutic tool for treating drug addictions. A pharmacologically important aspect of the contraction-reducing (antispasmodic) properties of ingested Salvinorin A on gut tissue is that it is only pharmacologically active on inflamed and not normal tissue, thus reducing possible side-effects.
Because failure to properly carry out any one of the components can severely affect the usefulness of using drug concentrations to optimize therapy, an organized approach to the overall process is critical.
Carbon dioxide occupies a different binding site on the hemoglobin. At tissues, where carbon dioxide concentration is higher, carbon dioxide binds to allosteric site of hemoglobin, facilitating unloading of oxygen from hemoglobin and ultimately its removal from the body after the oxygen has been released to tissues undergoing metabolism. This increased affinity for carbon dioxide by the venous blood is known as the Bohr effect. Through the enzyme carbonic anhydrase, carbon dioxide reacts with water to give carbonic acid, which decomposes into bicarbonate and protons:
Sources: en.wikipedia.org
== In popular culture == The 1960 British war film Sink the Bismarck! discusses the strategic importance of the GIUK gap during World War II naval operations in the Atlantic theatre, and depicts the Battle of the Denmark Strait between British and German forces. It is based on the novel The Last Nine Days of the Bismarck by C. S. Forester. The GIUK line is mentioned in the film The Bedford Incident. In Tom Clancy's first novel, The Hunt for Red October, the line was used to detect Soviet submarines entering the North Atlantic in pursuit of the rogue Typhoon-class submarine Red October, whose officers were defecting to the United States with clandestine stealth technology. The event causes significant political and military tension between the United States and the Soviet Union. The film adaptation also references the gap, with National Security Advisor Jeffrey Pelt (played by Richard Jordan) saying to the Soviet ambassador "Your aircraft have dropped enough sonar buoys so that a man could walk from Greenland to Iceland to Scotland without getting his feet wet." In Clancy's second novel, Red Storm Rising, the line is featured more prominently after a war breaks out between NATO and the Warsaw Pact. The Soviet Union launches a surprise attack on the NATO airbase NAS Keflavik and invades Iceland. This causes the line to be destroyed, creating a gap in NATO's surveillance and allowing the Soviet Navy to enter the North Atlantic.
=== The TRAIL gene as a drug target === TIC10 (which causes expression of TRAIL) was investigated in mice with various tumour types. Small molecule ONC201 causes expression of TRAIL which kills some cancer cells.
Proamylin, which is cosecreted with proinsulin, requires the above three factors and an amidating monooxygenase to convert itself to an active hormone. Some pro-protein precursors, such as preproinsulin, also go through this process, with the added step of removing a signal peptide by signal peptidases, to convert said precursors into prohormones.
The production of kimono started to use Western technologies such as synthetic dye, and decoration was sometimes influenced by Western motifs. The textile industry modernized rapidly and silk from Tokyo's factories became Japan's principal export. Cheap synthetic dyes meant that bold purples and reds, previously restricted to the wealthy elite, could be owned by anyone. Faster and cheaper manufacture allowed more people to afford silk kimono, and enabled designers to create new patterns. The Emperor issued a proclamation promoting Western dress over the allegedly effeminate Japanese dress. Fukuzawa Yukichi's descriptions of Western clothing and customs were influential. Western dress became popular in the public sphere: many men adopted Western dress in the workplace, although kimono were still the norm for men at home and for women. In the 1890s the kimono reasserted itself, with people wearing bolder and brighter styles. A new type called the hōmongi bridged the gap between formal dress and everyday dress. The technology of the time allowed for subtle color gradients rather than abrupt changes of color. Another trend was for outer and inner garments of the same design. Another trend in the Meiji era was for women's under-kimono made by combining pieces of different fabric, sometimes of radically different colors and designs. For men, the trend was for highly decorative under-kimono that would be covered by outer kimono that were plain or very simply designed.
=== Coastal ecosystems === Aquaculture is becoming a significant threat to coastal ecosystems. About 20 percent of mangrove forests have been destroyed since 1980, partly due to shrimp farming. An extended cost–benefit analysis of the total economic value of shrimp aquaculture built on mangrove ecosystems found that the external costs were much higher than the external benefits. Over four decades, 269,000 hectares (660,000 acres) of Indonesian mangroves have been converted to shrimp farms. Most of these farms are abandoned within a decade because of the toxin build-up and nutrient loss.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Purity is usually reported from reversed-phase high-performance liquid chromatography with ultraviolet detection. Peak area percentage gives a purity figure, though it does not prove identity. Mass spectrometry is used alongside chromatography to confirm the expected molecular mass.